S&CO Inc. Has $4.06 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

S&CO Inc. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 24.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 61,555 shares of the medical research company’s stock after purchasing an additional 12,120 shares during the quarter. S&CO Inc.’s holdings in Edwards Lifesciences were worth $4,062,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of EW. Park Avenue Securities LLC lifted its holdings in shares of Edwards Lifesciences by 0.5% during the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after acquiring an additional 108 shares during the period. City State Bank lifted its holdings in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after purchasing an additional 130 shares during the last quarter. Stableford Capital II LLC lifted its holdings in Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after purchasing an additional 159 shares during the last quarter. Purus Wealth Management LLC increased its position in Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after acquiring an additional 160 shares in the last quarter. Finally, Busey Bank increased its position in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 165 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Citigroup lowered their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $75.67.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,133,916.72. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock valued at $2,744,438 in the last quarter. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $67.76 on Friday. The business has a 50 day moving average of $67.44 and a 200-day moving average of $76.18. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $39.96 billion, a P/E ratio of 9.78, a P/E/G ratio of 3.81 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 EPS. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.